Cargando…

Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies

Structural variants (SV) are changes in the genomic landscape that can alter gene expression levels and thus lead to disease development. The most common and best studied SVs in hematological malignancies are chromosomal translocations. Here, parts of two genes that are normally on different chromos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schütte, Judith, Reusch, Julia, Khandanpour, Cyrus, Eisfeld, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722867/ https://www.ncbi.nlm.nih.gov/pubmed/31555592 http://dx.doi.org/10.3389/fonc.2019.00839

Ejemplares similares

Editorial: New emerging functions of transcription factors and RNA-binding proteins in the development of hematological malignancies
por: Möröy, Tarik, et al.
Publicado: (2023)

Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications
por: Möröy, Tarik, et al.
Publicado: (2019)

Advanced Targeted, Cell and Gene-Therapy Approaches for Pediatric Hematological Malignancies: Results and Future Perspectives
por: Magnani, Chiara F., et al.
Publicado: (2013)

Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
por: De Veirman, Kim, et al.
Publicado: (2014)

Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy
por: Zhang, Leqiang, et al.
Publicado: (2022)

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
por: Jin, Shenhe, et al.
Publicado: (2022)

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
por: Khandanpour, Cyrus, et al.
Publicado: (2021)

Semaphorins and Their Receptors in Hematological Malignancies
por: Wei, Li, et al.
Publicado: (2019)

WNT Signaling in Hematological Malignancies
por: Frenquelli, Michela, et al.
Publicado: (2020)

Editorial: Reviews in hematologic malignancies
por: Saraceni, Francesco, et al.
Publicado: (2022)

Checkpoint inhibition in hematologic malignancies
por: Tsumura, Aaron, et al.
Publicado: (2023)

Ferroptosis in hematological malignant tumors
por: Liu, Yong, et al.
Publicado: (2023)

From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies
por: Ciccone, Maria, et al.
Publicado: (2015)

The RNA helicase DDX3 and its role in c-MYC driven germinal center-derived B-cell lymphoma
por: Lacroix, Marion, et al.
Publicado: (2023)

Cellular Therapies for the Treatment of Hematological Malignancies; Swine Are an Ideal Preclinical Model
por: Duran-Struuck, Raimon, et al.
Publicado: (2019)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
por: Tasian, Sarah K., et al.
Publicado: (2014)

Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets
por: Ding, Ziyang, et al.
Publicado: (2023)

Cap-Independent Translation in Hematological Malignancies
por: Horvilleur, Emilie, et al.
Publicado: (2015)

Multiple Roles of Glycans in Hematological Malignancies
por: Pang, Xingchen, et al.
Publicado: (2018)

PHF6 Mutations in Hematologic Malignancies
por: Kurzer, Jason H., et al.
Publicado: (2021)

The hedgehog pathway in hematopoiesis and hematological malignancy
por: Lemos, Tucker, et al.
Publicado: (2022)

Editorial: Epidemiological trends in hematological malignancies
por: de Lima, Marcos, et al.
Publicado: (2023)

Bone Marrow Senescence and the Microenvironment of Hematological Malignancies
por: Hellmich, Charlotte, et al.
Publicado: (2020)

Editorial: Rising Stars in Hematologic Malignancies 2021
por: Qian, Liren, et al.
Publicado: (2022)

Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies
por: Zuo, Fengli, et al.
Publicado: (2022)

Arginase: Mechanisms and Clinical Application in Hematologic Malignancy
por: Du, Zefan, et al.
Publicado: (2022)

Advances in the Study of circRNAs in Hematological Malignancies
por: Du, Jingyi, et al.
Publicado: (2022)

Editorial: Linking cellular metabolism to hematological malignancies
por: He, Xiujing, et al.
Publicado: (2022)

Editorial: Measurable residual disease in hematologic malignancies
por: Buccisano, Francesco, et al.
Publicado: (2023)

Editorial: Tumour microenvironment heterogeneity in hematological malignancies
por: Deaglio, Silvia, et al.
Publicado: (2023)

Germline and somatic drivers in inherited hematologic malignancies
por: Zoller, Julian, et al.
Publicado: (2023)

Editorial: Case reports in hematological malignancies: 2022
por: Antar, Ahmad, et al.
Publicado: (2023)

Case Report: Infectious prophylaxis in hematological malignancies
por: Passucci, Mauro, et al.
Publicado: (2023)

The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma
por: Sandmann, Sarah, et al.
Publicado: (2022)

Benefit of continuous kidney replacement therapy for managing tumor lysis syndrome in children with hematologic malignancies
por: Anderson, Ashlea, et al.
Publicado: (2023)

Crosstalk Between MYC and lncRNAs in Hematological Malignancies
por: Arman, Kaifee, et al.
Publicado: (2020)

Screening Strategies for COVID-19 in Patients With Hematologic Malignancies
por: Assi, Tarek, et al.
Publicado: (2020)

Molecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies
por: Zhao, Yan, et al.
Publicado: (2021)

The Role of Exosomes in the Progression and Therapeutic Resistance of Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2022)

Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies
por: Xie, Yutong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j9a88o1h0k8tnrb9nlos78p3io